PBAC's latest decision on Levodopa with carbidopa: Recommended with restriction (2016). Considered for Advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2008
Submissions
3
2008 → 2016
Eligible population
Patients with advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy, commenced on treatment in a hospital-based movement disorder clinic, with adequate cognitive function to manage administration with a portable continuous infusion pump.
Therapy area
Neurology
Line of therapy
Maintenance therapy
Evidence base
Other
Economic model
not-modelled
ICER note
Minor submission with no economic comparison.
ICER (historical)
$45k/QALY–$75k/QALY across 2 submissions (2008–2010) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2008: Not recommended · Authority Required — ICER $75k/QALY
Nov 2010: Recommended with restriction · Restricted — ICER $75k/QALY
Nov 2016: Recommended with restriction · Restricted